Innovating Works
IMI2-2014-01-01
IMI2-2014-01-01: Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)
Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function & beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 12-11-2014.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function & beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking.

Please refer to the full topic text on the IMI2 Call 1 section of the IMI website: http://www.imi.europa.eu/content/stage-1-13

Scope:  The overall aim of the project is to significantly progress the understanding of the T1DM disease and its patients by bringing together leading clinicians and researcher from the... ver más

Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function & beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking.

Please refer to the full topic text on the IMI2 Call 1 section of the IMI website: http://www.imi.europa.eu/content/stage-1-13

Scope:  The overall aim of the project is to significantly progress the understanding of the T1DM disease and its patients by bringing together leading clinicians and researcher from the areas of Immunology, Beta cell biology, and biomarker research from academia and industry. It is expected that this initiative will significantly progress the molecular understanding of the pathophysiology of T1DM and of the impact provided by standard of medical care upon T1DM patients.

Please refer to the full topic text on the IMI2 Call 1 section of the IMI website.

Expected impact: The project should help gain an improved molecular understanding of the T1DM patients, deliver insights into the  disease heterogeneity and provide tools for identification of high-risk patients. Ultimately the outcome will be the definition and refinement of T1DM disease taxonomy which could create a foundation for personalized therapy of T1DM patients.

Please refer to the full topic text on the IMI2 Call 1 section of the IMI website.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function & beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking. Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function & beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
For full information on this call, please refer to the IMI website.
Please note that submitting short proposals for this call can only by done through the IMI SOFIA sotware tool.
 
Please read the IMI2 1st Call for Proposals 2014 Call text for full details of this topic, including the budget breakdown.
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award.  See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in the IMI2 RIA/IA evaluation form and in the IMI2 Manual for submission, evaluation and grant award.
3.2 Guide to the submission and evaluation process: described in the IMI2 Manual for submission, evaluation and grant award and the IMI2 RIA/IA proposal template.
 
Proposal page limits and layout: Please refer to the IMI2 RIA/IA proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the fin...
For full information on this call, please refer to the IMI website.
Please note that submitting short proposals for this call can only by done through the IMI SOFIA sotware tool.
 
Please read the IMI2 1st Call for Proposals 2014 Call text for full details of this topic, including the budget breakdown.
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award.  See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in the IMI2 RIA/IA evaluation form and in the IMI2 Manual for submission, evaluation and grant award.
3.2 Guide to the submission and evaluation process: described in the IMI2 Manual for submission, evaluation and grant award and the IMI2 RIA/IA proposal template.
 
Proposal page limits and layout: Please refer to the IMI2 RIA/IA proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
 
 
Provisions, proposal templates and evaluation forms for IMI2 Research and Innovation Actions
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 RIA/IA Proposal template
IMI2 RIA/IA Evaluation form
IMI2 Model Grant Agreement
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2014-01-two-stage Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM) Scope:Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 Million people. The disease T1D...
Sin info.
IMI2-2014-02-03 Stability of vaccines during transport and storage
en consorcio: Scope:Specific challenge Currently available vaccine candidates need to be stored and transported at low temperature to maintain activity....
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
IMI2-2014-02-02 Manufacturing capability
en consorcio: Scope:Specific challenge In view of the current epidemic, the WHO has identified the progression of vaccine candidates currently in develo...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
IMI2-2014-02-01 Vaccine development Phase I, II, and III
en consorcio: Scope:Specific challenge In view of the current epidemic, the WHO has identified the progression of vaccine candidates currently in develo...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
IMI2-2014-02-05 Rapid diagnostic tests
en consorcio: Scope:Specific challenge Rapid detection of Ebola infections in the field or at decentralised healthcare centers is an urgent need in the...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de
IMI2-2014-02-04 Deployment and compliance of vaccination regimens
en consorcio: Scope:Specific challenge To control the epidemic, ensuring vaccination coverage is of critical importance.  In addition, to ensure lasting...
Cerrada hace 10 años | Próxima convocatoria prevista para el mes de